EBMT China’s Voice | Professor Chunfu Li ‘s Team: Relationship between Immune Reconstitution, Graft-versus-Host Disease, and Viral Infections in Patients with Beta-Thalassemia Major Treated with Different Sources of Stem Cell Transplantation

EBMT China’s Voice | Professor Chunfu Li ‘s Team: Relationship between Immune Reconstitution, Graft-versus-Host Disease, and Viral Infections in Patients with Beta-Thalassemia Major Treated with Different Sources of Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is the classical treatment for curing beta-thalassemia major. With the continuous maturity of HSCT technology and supportive therapy over the past two decades, the choice of HSCT methods has expanded from classical matched sibling donor transplantation to matched unrelated donor transplantation and haploidentical transplantation. The commonly used stem cell types have also gradually transitioned from bone marrow hematopoietic stem cells to mobilized peripheral blood stem cells. Additionally, cord blood stem cells from related or unrelated donors have been widely used. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, United Kingdom. The conference focused on the latest advances in stem cell transplantation and cell therapy, driving towards better clinical outcomes for patients with hematological diseases and hematologic malignancies. At the meeting, Professor Chunfu Li from the Southern Chunfu (Pediatric) Hematology Research Institute, High-performance Medicine (Hematology) Guangdong Research Center, reported a clinical study comparing immune reconstitution, graft-versus-host disease (GVHD), and viral infections in patients with beta-thalassemia major treated with stem cell transplantation from different sources. The following is a compiled summary of the content for readers' enjoyment.
Professor Zhongxing Jiang: Focusing on the diagnosis and treatment of chronic disease-related anemia to improve patient quality of life | The 19th National Conference on Red Blood Cell Diseases (Anemia) by the Chinese Medical Association

Professor Zhongxing Jiang: Focusing on the diagnosis and treatment of chronic disease-related anemia to improve patient quality of life | The 19th National Conference on Red Blood Cell Diseases (Anemia) by the Chinese Medical Association

Chronic disease-related anemia, as one of the most common types of anemia, is the most common type of anemia among hospitalized patients and elderly individuals. Chronic disease-related anemia is usually accompanied by underlying diseases, with complex causes and diverse symptoms, distributed across multiple departments. Clinical doctors should pay sufficient attention to it in order to achieve better treatment outcomes. At the recent 19th National Conference on Red Blood Cell Diseases (Anemia) hosted by the Chinese Medical Association, Professor Zhongxing Jiang from The First Affiliated Hospital of Zhengzhou University shared the progress and prospects of the diagnosis and treatment of chronic disease-related anemia with Oncology Frontier - Hematology Frontier.
EBMT China’s Voice | Professor Yue Lu: Haploidentical Hematopoietic Stem Cell Transplantation Using Non-Direct Related Donors vs. Direct Related Donors – Similarity in Efficacy and Safety

EBMT China’s Voice | Professor Yue Lu: Haploidentical Hematopoietic Stem Cell Transplantation Using Non-Direct Related Donors vs. Direct Related Donors – Similarity in Efficacy and Safety

In recent years, haploidentical donor hematopoietic stem cell transplantation has gradually been developed in malignant hematologic tumors, greatly solving the problem of previous donor shortages. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, the third-largest city in the UK. At this EBMT Annual Meeting, Professor Yue Lu from Lu Daopei Hospital reported on a latest clinical research result. The study confirmed that in haploidentical hematopoietic stem cell transplantation, using non-direct related donors can be comparable to direct related donors in terms of efficacy and safety. This also provides further evidence to expand the range of selectable donors in clinical practice. Our journal invited Professor Yue Lu to share the important results and clinical significance of this study with colleagues.
EBMT China’s Voice | Professors XiaoyanKe and KaiHu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

EBMT China’s Voice | Professors XiaoyanKe and KaiHu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.
Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma: Highlights from the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference

Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma: Highlights from the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference

From March 23rd to 24th, 2024, the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference, hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, and co-organized by the First Affiliated Hospital of Soochow University, was successfully held in Suzhou, Jiangsu Province, China. Numerous hematological experts and scholars from China and abroad engaged in academic exchanges on experimental diagnosis in the field of hematological diseases and the latest developments in rare blood diseases through academic presentations and thematic discussions.During the conference, Professor Bing Xiang from West China Hospital of Sichuan University delivered an insightful presentation titled "Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma." In this article, we summarize the main points of the presentation for the benefit of our readers.
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

In the challenging field of hematology, the search for effective treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after CAR-T therapy failure is crucial. Professor Professor Haiwen Huang from The First Affiliated Hospital of Soochow University leads an innovative study exploring allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a promising alternative. This collaborative research not only offers new hope for R/R DLBCL patients but also showcases the pioneering spirit driving advancements in oncology. By providing valuable insights into allo-HSCT's potential, Professor Huang and his team contribute significantly to the evolving landscape of cancer treatment, highlighting the importance of innovation and teamwork in improving patient care.
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

Professor Haiwen Huang from The First Affiliated Hospital of Soochow University provided an enlightening discourse on the significant strides made in CAR T cell therapies, with a special emphasis on their pioneering work in FcRH5 CAR-T cells for multiple myeloma. The study not only showcased the remarkable journey of hematology research over the years but also spotlighted the transformative potential of next-generation CAR T cell therapies in offering new hope to patients with hematologic cancers.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory marginal zone lymphoma are of paramount importance. It is in this context that the recent phase 2, multicenter, open-label study investigating the efficacy of Orelabrutinib comes to light, marking a significant advancement in the therapeutic domain. This study, meticulously carried out by a dedicated team of researchers led by Professor Haiwen Huang from The First Affiliated Hospital of Soochow University, alongside esteemed colleagues from various prestigious institutions across China, has been a beacon of hope for patients grappling with this relentless malignancy. The findings of this groundbreaking research were meticulously documented in the American Journal of Hematology, underscoring not only the potential of Orelabrutinib as a viable treatment option but also the collaborative effort and expertise that epitomizes the spirit of innovation in the field. This endeavor, emblematic of the strides being made in hematology research, was brilliantly showcased during a session at the renowned Beijing Hematologic Tumor and Immunology Summit Forum, an event that has become a cornerstone for the dissemination of cutting-edge scientific knowledge and clinical practices.